Psyence Group Inc.

CNSX: PSYG


Canadian symbol: PSYG.CN
US symbol: PSYGF

Currency in CAD

Valuation Measures4

Market Cap (intraday) 9.84M
Enterprise Value 8.84M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)N/A
Price/Book (mrq)6.22
Enterprise Value/Revenue N/A
Enterprise Value/EBITDA -1.96

Trading Information

Stock Price History

Beta (5Y Monthly) N/A
52-Week Change 3-30.30%
S&P500 52-Week Change 3-13.12%
52 Week High 30.2050
52 Week Low 30.0100
50-Day Moving Average 30.1125
200-Day Moving Average 30.1011

Share Statistics

Avg Vol (3 month) 319.03k
Avg Vol (10 day) 336.37k
Shares Outstanding 585.53M
Implied Shares Outstanding 6N/A
Float 876.33M
% Held by Insiders 112.63%
% Held by Institutions 10.00%
Shares Short (Oct 13, 2022) 432.99k
Short Ratio (Oct 13, 2022) 41.3
Short % of Float (Oct 13, 2022) 4N/A
Short % of Shares Outstanding (Oct 13, 2022) 40.04%
Shares Short (prior month Sept 14, 2022) 4449

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Mar 30, 2022
Most Recent Quarter (mrq)Jun 29, 2022

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-60.15%
Return on Equity (ttm)-127.22%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -4.4M
Net Income Avi to Common (ttm)-4.57M
Diluted EPS (ttm)-0.1780
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)2.32M
Total Cash Per Share (mrq)0.03
Total Debt (mrq)1.32M
Total Debt/Equity (mrq)83.75
Current Ratio (mrq)1.50
Book Value Per Share (mrq)0.02

Cash Flow Statement

Operating Cash Flow (ttm)-3.72M
Levered Free Cash Flow (ttm)-3.27M

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen



Warning: Use of undefined constant SITE_CONFIG_TWITTER_ACCOUNT - assumed 'SITE_CONFIG_TWITTER_ACCOUNT' (this will throw an Error in a future version of PHP) in /var/www/vhosts/shroominvestor.com/httpdocs/web/app/themes/15zine-child/module-stock-news.php on line 10



Notice: Undefined variable: current_category_name in /var/www/vhosts/shroominvestor.com/httpdocs/web/app/themes/15zine-child/module-stock-news.php on line 247

Psychedelics News and Psilocybin Investing

Real-time news from hundreds of sources. Never miss the news that matters the most.


Notice: Undefined index: newsCategory in /var/www/vhosts/shroominvestor.com/httpdocs/web/app/themes/15zine-child/module-stock-news.php on line 363

Notice: Undefined index: stockNewsCategory in /var/www/vhosts/shroominvestor.com/httpdocs/web/app/themes/15zine-child/module-stock-news.php on line 363



Company News Date
PSYG.CN
Psyence Group
2 months ago
PSYG.CN
Psyence Group
2 months ago
PSYG.CN
Psyence Group
2 months ago
PSYG.CN
Psyence Group
2 months ago
PSYG.CN
Psyence Group
7 months ago
PSYG.CN
Psyence Group
7 months ago
PSYG.CN
Psyence Group
7 months ago
PSYG.CN
Psyence Group
9 months ago
PSYG.CN
Psyence Group
10 months ago
PSYG.CN
Psyence Group
1 year ago
PSYG.CN
Psyence Group
1 year ago
PSYG.CN
Psyence Group
1 year ago
PSYG.CN
Psyence Group
1 year ago
PSYG.CN
Psyence Group
1 year ago
PSYG.CN
Psyence Group
1 year ago
PSYG.CN
Psyence Group
1 year ago
PSYG.CN
Psyence Group
1 year ago
PSYG.CN
Psyence Group
1 year ago

Notice: Undefined index: newsCategory in /var/www/vhosts/shroominvestor.com/httpdocs/web/app/themes/15zine-child/module-stock-news.php on line 710


Notice: A non well formed numeric value encountered in /var/www/vhosts/shroominvestor.com/httpdocs/web/functions_stocks.php on line 626
Currency in CAD
Earnings EstimateCurrent Qtr.Next Qtr.Current YearNext Year
No. of Analysts0000
Avg. Estimate0000
Low Estimate0000
High Estimate0000
Year Ago EPSN/AN/AN/AN/A
Revenue EstimateCurrent Qtr.Next Qtr.Current YearNext Year
No. of Analysts0000
Avg. EstimateN/AN/AN/AN/A
Low EstimateN/AN/AN/AN/A
High EstimateN/AN/AN/AN/A
Year Ago SalesN/AN/AN/AN/A
Sales Growth (year/est)N/AN/AN/AN/A
Earnings HistoryInvalid DateInvalid DateInvalid DateInvalid Date
EPS Est.N/AN/AN/AN/A
EPS ActualN/AN/AN/AN/A
DifferenceN/AN/AN/AN/A
Surprise %N/AN/AN/AN/A
EPS TrendCurrent Qtr.Next Qtr.Current YearNext Year
Current Estimate0000
7 Days Ago0000
30 Days Ago0000
60 Days Ago0000
90 Days Ago0000
EPS RevisionsCurrent Qtr.Next Qtr.Current YearNext Year
Up Last 7 DaysN/AN/AN/AN/A
Up Last 30 DaysN/AN/AN/AN/A
Down Last 7 DaysN/AN/AN/AN/A
Down Last 30 DaysN/AN/AN/AN/A
Growth EstimatesPSYG.CNIndustrySector(s)S&P 500
Current Qtr.N/AN/AN/AN/A
Next Qtr.N/AN/AN/AN/A
Current YearN/AN/AN/AN/A
Next YearN/AN/AN/AN/A
Next 5 Years (per annum)N/AN/AN/AN/A
Past 5 Years (per annum)N/AN/AN/AN/A

Notice: Undefined variable: insiders_html in /var/www/vhosts/shroominvestor.com/httpdocs/web/app/themes/15zine-child/template-company-details.php on line 711


Insiders transactions are updated every hour.

Notice: A non well formed numeric value encountered in /var/www/vhosts/shroominvestor.com/httpdocs/web/functions_stocks.php on line 626

Major Holders

Currency in CAD
Breakdown
12.63%% of Shares Held by All Insider
0.00%% of Shares Held by Institutions
0.00%% of Float Held by Institutions
0Number of Institutions Holding Shares
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by Psyence Group Inc.


GOODMIND™ Available for Sale in the United Kingdom and Europe – Exclusive Distribution Agreement Concluded With This Works

TORONTO, Nov. 29, 2022 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that it has, together with its joint venture partner The Goodleaf Company (Pty) Ltd (“Goodleaf”), ente... Read More...

Psyence Group Receives Phase IIa Clinical Trial Approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA)

TORONTO, Sept. 19, 2022 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) ("Psyence" or the "Company"), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is delighted to announce that it has received approval for its Phase IIa clinical trial from the Medicines and Healthcare pr... Read More...

Psyence Group Announces DTC Eligibility Approval in the U.S.

TORONTO, Feb. 09, 2022 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that the Company’s common shares are now eligible for electronic clearing and settlement through the D... Read More...

Psyence Awarded ISO Certification through the British Standards Institute for its Natural Psilocybin Production Facility

TORONTO, Feb. 07, 2022 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that its ISO22000 graded Psilocybin production facility has officially received International Organiza... Read More...

Psyence to Present at the H.C Wainwright 2nd Annual Psychedelics Conference December 6

TORONTO, Dec. 03, 2021 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that Psyence Chief Executive Officer, Neil Maresky, will be presenting at the virtual H.C. Wainwright ... Read More...

Psyence Group Announces Private Placement

TORONTO, Dec. 02, 2021 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, announces that it is commencing a non-brokered private placement offering of up to CAD$2,000,000 of unsecured convertible pro... Read More...

Psyence Group Functional Mushroom Brand “GOODMIND™” Commences National Roll-Out in South Africa’s Largest Coffee Retail Chain

Company Broadens Revenue Generation InitiativesGOODMIND™Elevate your daily grind / GOODMIND™Elevate your daily grind / GOODMIND™TORONTO, Dec. 02, 2021 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-bein... Read More...

Psyence Group Inc. files Q2 Unaudited Condensed Consolidated Interim Financial Statements and MD&A

TORONTO, Nov. 26, 2021 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company with a focus on natural psychedelics in mental health and well-being, announces that the Unaudited Condensed Consolidated Interim Financial Statements for the six months period ended September 30, 2021... Read More...

Psyence Group Invited as First Psychedelic Company to present at the 15th-Annual Global Wellness Summit

TORONTO, Nov. 26, 2021 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company with a focus on natural psychedelics in mental health and well-being, will break new ground as the first psychedelic company invited to speak at the 15th Annual Global Wellness Summit, a gathering of i... Read More...

Psyence Group Announces Commencement of Trading on OTCQB and DTC Eligibility of Common Shares in the United States Under the Ticker “PSYGF”

TORONTO, Oct. 13, 2021 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that, effective today, its common shares have been approved for trading on the OTCQB® Venture Market (... Read More...

Psyence Group and Pure Extracts Finalize “Pure Psyence,” A Joint Venture for the Development of Psychedelic Medicinal Mushroom Extracts

A Canadian partnership with international ties to advance the field of psychedelic medicine globally with standardized extractsA leader in naturally-derived psilocybin for extraction, production of advanced formulations and clinical research TORONTO, Sept. 28, 2021 -- Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”) and Pure Ex... Read More...

Psyence Group Announces the Commencement of Online Sales and Distribution of “GOODMIND” Products

TORONTO and CAPE TOWN, South Africa, Aug. 18, 2021 -- Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce the commencement of online sales and distribution of its premium range of functional mush... Read More...

Psyence Group and UK Psychedelic CRO Partners to Conduct UK Palliative Care Clinical Trial

TORONTO, July 07, 2021 -- Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce it has signed a partnership agreement with Clerkenwell Health (“Clerkenwell”). Clerkenwell is a leading psychedelic C... Read More...

Psyence Group Corporate Update

TORONTO, May 27, 2021 -- Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”) is pleased to provide the following corporate update on its three clear paths to revenue and value creation namely: Psyence Production, Psyence Therapeutics and Psyence Function.Psyence ProductionPsyence is federally licensed to cultivate and export psilo... Read More...

The Psyence Group Announces its Formal Entry into Jamaica with the Incorporation of its Wholly Owned Subsidiary, Psyence Jamaica Limited

TORONTO, June 08, 2021 -- Psyence Group Inc. (“Psyence” or the “Company”) (PSYG:CSE), a Canadian public biotechnology company with a global presence, is pleased to announce the incorporation, and operational commencement, of its wholly owned Jamaican subsidiary, “Psyence Jamaica Limited” (“Psyence Jamaica”).The Psyence Group has been oper... Read More...
Coming Soon.

Notice: A non well formed numeric value encountered in /var/www/vhosts/shroominvestor.com/httpdocs/web/functions_stocks.php on line 626
IndexLast% Change
S&P 5003,998.841.79%Negative
Euro STOXX 503,956.53--
FTSE 1007,567.540.15%Positive
Nikkei 22527,923.060.37%Positive

Delayed data (1h)

Notice: A non well formed numeric value encountered in /var/www/vhosts/shroominvestor.com/httpdocs/web/functions_stocks.php on line 626
IndexLast% Change
S&P 5003,998.841.79%Negative
Euro STOXX 503,956.53--
FTSE 1007,567.540.15%Positive
Nikkei 22527,923.060.37%Positive


Share this page